# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number k190968   
B Applicant Microgenics Corporation   
C Proprietary and Established Names CEDIATM Benzodiazepine Assay   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>JXM</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.3170 -Benzodiazepine TestSystem</td><td rowspan=1 colspan=1>TX - ClinicalToxicology</td></tr></table>

# II Submission/Device Overview:

A Purpose for Submission: New device   
B Measurand: Benzodiazepines   
C Type of Test:

Qualitative and semi-quantitative homogeneous immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s):

See Indications for Use below.

# B Indication(s) for Use:

The CEDIATM Benzodiazepine Assay is a homogeneous enzyme immunoassay intended for the qualitative and/or semiquantitative determination of benzodiazepines in human urine at a cutoff concentration of $2 0 0 ~ \mathrm { { n g / m L } }$ .

The semi-quantitative mode is for the purpose of enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as Liquid Chromatography/tandem mass spectrometry (LC-MS/MS) or permitting laboratories to establish quality control procedures.

The assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography / Mass spectrometry (GC/MS) or Liquid chromatography/tandem mass spectrometry (LC-MS/MS) is the preferred confirmatory method.

Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary results are used. For In Vitro Diagnostic Use Only.

C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

D Special Instrument Requirements:

Performance data was obtained using the Beckman AU680 clinical chemistry analyzer.

# IV Device/System Characteristics:

# A Device Description:

The assay consists of two lyophilized and two liquid reagents:

EA Reconstitution Buffer and ED Reconstitution Buffer: (lyophilized)   
EA Reagent and ED Reagent (liquid ready to-use)   
$\beta$ -Glucuronidase reagent

The components include sheep polyclonal anti-benzodiazepine antibody, recombinant microbial “enzyme donor” – benzodiazepine conjugate, “enzyme acceptor”, chlorophenol red $\beta$ -Dgalactopyranoside, stabilizers and preservatives. All specimens must be tested with $\beta \mathrm { . }$ - glucuronidase enzyme. Add $\beta$ -glucuronidase enzyme to the reconstituted EA solution before using the assay. This enzyme will hydrolyze the glucuronidated metabolites of benzodiazepines in the samples, thereby enabling the detection of benzodiazepine glucuronides.

# B Principle of Operation:

CEDIATM technology uses recombinant DNA technology to produce a unique homogeneous enzyme immunoassay system. The assay is based on the bacterial enzyme $\beta \mathrm { . }$ -galactosidase, which has been genetically engineered into two inactive fragments, Enzyme acceptor (EA) and Enzyme Donor (ED). These fragments spontaneously re-associate to form fully active enzyme that, in the assay format, cleaves a substrate. This generates a color change that can be measured spectrophotometrically.

V Substantial Equivalence Information:

A Predicate Device Name(s): CEDIATM DAU Benzodiazepine Assay B Predicate 510(k) Number(s): k962734 C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">k190968</td><td colspan="1" rowspan="1">k962734</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">CEDIATMBenzodiazepine Assay</td><td colspan="1" rowspan="1">CEDIATM DAUBenzodiazepine Assay</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Similarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/IndicationsFor Use</td><td colspan="1" rowspan="1">Intended for thequalitative andsemiquantitativeassay ofbenzodiazepines inhuman urine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measured Analyte</td><td colspan="1" rowspan="1">Benzodiazepine and itsmetabolites</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Antibody</td><td colspan="1" rowspan="1">Polyclonal sheepantibody</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Test Matrix</td><td colspan="1" rowspan="1">Urine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Homogeneous enzymeimmunoassay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Differences</td><td colspan="1" rowspan="1">CEDIATMBenzodiazepine Assay</td><td colspan="1" rowspan="1">CEDIATM DAUBenzodiazepine Assay</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">Nitrazepam</td></tr><tr><td colspan="1" rowspan="1">Cutoff Levels</td><td colspan="1" rowspan="1">200 ng/mL HighSensitivity</td><td colspan="1" rowspan="1">200 ng/mL or 300ng/mL</td></tr></table>

# VI Standards/Guidance Documents Referenced:

CLSI EP05-A3 – Evaluation of Precision of Quantitative Measurement Procedures;   
Approved Guideline – Third Edition.   
CLSI EP06-A – Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline.   
CLSI EP07-A2 – Interference Testing In Clinical Chemistry; Approved Guideline – Second Edition   
CLSI EP25-A – Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

The precision study was performed using CLSI Guideline EP05-A3 as a guideline. Testing was carried out for 20 days with two runs per day, at least two hours apart and two replicates per run in both Qualitative and Semi-quantitative modes, giving a total of 80 determinants (n $= 8 0$ ). Drug-free negative urine was spiked with Oxazepam to final concentrations of $- 1 0 0 \%$ , $- 7 5 \%$ , $- 5 0 \%$ , $- 2 5 \%$ , below cutoff and $+ 2 5 \%$ , $+ 5 0 \%$ , $+ 7 5 \%$ and $+ 1 0 0 \%$ , above cutoff, and the spikes were confirmed by LC-MS/MS.

Qualitative Mode for $2 0 0 ~ \mathrm { { n g / m l } }$ cutoff:   

<table><tr><td rowspan=1 colspan=1>% of Cutoff(200 ng/mL)</td><td rowspan=1 colspan=1>Targetconcentration(ng/mL)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1># Negative /# Positive</td></tr><tr><td rowspan=1 colspan=1>-100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>-75</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>-50</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>-25</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>6/74</td></tr><tr><td rowspan=1 colspan=1>+25</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>+50</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>+75</td><td rowspan=1 colspan=1>350</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>+100</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr></table>

Semi-Quantitative Mode for $2 0 0 \mathrm { n g / m l }$ cutoff:   

<table><tr><td rowspan=1 colspan=1>% of Cutoff(200 ng/mL)</td><td rowspan=1 colspan=1>Targetconcentration(ng/mL)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1># Negative /# Positive</td></tr><tr><td rowspan=1 colspan=1>-100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>-75</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>-50</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>-25</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>79/1</td></tr><tr><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1/79</td></tr><tr><td rowspan=1 colspan=1>+25</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>+50</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>+75</td><td rowspan=1 colspan=1>350</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>+100</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr></table>

Linearity:

A linearity study was performed using CLSI EP06-A guidelines. To demonstrate the dilution linearity for purposes of sample dilution and quality control up to $8 0 0 ~ \mathrm { { n g / m L } }$ assay range, drug free urine was spiked to $9 0 0 ~ \mathrm { { n g / m L } }$ level calibrator using Oxazepam and diluted with drug free urine to generate 8 intermediate levels. Each sample was run in replicates of five in semi-quantitative mode and the average was used to determine percent recovery compared to the expected target value. The average percent recovery is summarized in the table below.

<table><tr><td rowspan=1 colspan=1>ExpectedConcentration(ng/mL)</td><td rowspan=1 colspan=1>Observedconcentration(ng/mL)</td><td rowspan=1 colspan=1>AverageRecovery (%)</td><td rowspan=1 colspan=1>Rangeof Recovery (%)</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-1.00</td><td rowspan=1 colspan=1>N/A</td><td rowspan=10 colspan=1>95.2 - 107.8</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>115.6107.8</td><td rowspan=1 colspan=1>115.60107.8</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>198.0205.8</td><td rowspan=1 colspan=1>99.00102.9</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>304.4289.4</td><td rowspan=1 colspan=1>101.4796.5</td></tr><tr><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>448.6412.4</td><td rowspan=1 colspan=1>112.15103.1</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>517.2</td><td rowspan=1 colspan=1>116.16103.4</td></tr><tr><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>595.0</td><td rowspan=1 colspan=1>109.5099.2</td></tr><tr><td rowspan=1 colspan=1>700</td><td rowspan=1 colspan=1>732.6666.2</td><td rowspan=1 colspan=1>104.6695.2</td></tr><tr><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>766.2</td><td rowspan=1 colspan=1>118.8095.8</td></tr><tr><td rowspan=1 colspan=1>900</td><td rowspan=1 colspan=1>907.6</td><td rowspan=1 colspan=1>131.16100.8</td></tr></table>

# 2. Analytical Specificity/Interference:

# Cross-Reactivity of Benzodiazepine Compounds and Metabolites

The cross-reactivity of benzodiazepine compounds and their metabolites was evaluated by adding known amounts of each compound to drug-free negative urine. The specificity (cross-reactivity) study was performed using one lot of reagents, calibrators and controls in both qualitative and semi-quantitative modes. Percent cross-reactivity was calculated as (cutoff concentration / lowest concentration of cross reactant that gives a positive result) $\textbf { x } 1 0 0$ . Results are summarized below:

Cross Reactivity of Benzodiazepines and Metabolites- High Sensitivity $2 0 0 ~ \mathrm { { n g / m L } }$ Cutoff   

<table><tr><td rowspan=1 colspan=1>Benzodiazepine andmetabolites</td><td rowspan=1 colspan=1>Lowest concentrationproducing a positiveresult (ng/mL)</td><td rowspan=1 colspan=1>Cross-reactivity(%)</td></tr><tr><td rowspan=1 colspan=1>α-Hydroxyalprazolam</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>182</td></tr><tr><td rowspan=1 colspan=1>α-Hydroxytriazolam</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>143</td></tr><tr><td rowspan=1 colspan=1>Alprazolam</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>7-Aminoclonazepam</td><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>7-Aminoflunitrazepam</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>89</td></tr><tr><td rowspan=1 colspan=1>7-Aminonitrazepam</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Bromazepam</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>67</td></tr><tr><td rowspan=1 colspan=1>Chlordiazepoxide</td><td rowspan=1 colspan=1>2000</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>Clobazam</td><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>44</td></tr><tr><td rowspan=1 colspan=1>Clonazepam</td><td rowspan=1 colspan=1>350</td><td rowspan=1 colspan=1>57</td></tr><tr><td rowspan=1 colspan=1>Clorazepate</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Delorazepam</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Demoxepam</td><td rowspan=1 colspan=1>1500</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Desalkylflurazepam(Norfludiazepam)</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>182</td></tr><tr><td rowspan=1 colspan=1>Diazepam</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>250</td></tr><tr><td rowspan=1 colspan=1>Estazolam</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>174</td></tr><tr><td rowspan=1 colspan=1>Flunitrazepam</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>160</td></tr><tr><td rowspan=1 colspan=1>Flurazepam</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>286</td></tr><tr><td rowspan=1 colspan=1>Lorazepam</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Lorazepam glucuronide</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Lormetazepam</td><td rowspan=1 colspan=1>175</td><td rowspan=1 colspan=1>114</td></tr><tr><td rowspan=1 colspan=1>Medazepam</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Nitrazepam</td><td rowspan=1 colspan=1>290</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Nordiazepam(Desmethyldiazepam)</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>286</td></tr><tr><td rowspan=1 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Oxazepam glucuronide</td><td rowspan=1 colspan=1>350</td><td rowspan=1 colspan=1>57</td></tr><tr><td rowspan=1 colspan=1>Prazepam</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>143</td></tr><tr><td rowspan=1 colspan=1>Temazepam</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>154</td></tr><tr><td rowspan=1 colspan=1>Temazepam glucuronide</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Triazolam</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>222</td></tr></table>

# Interference Testing of Structurally Unrelated Compounds

Interference from structurally unrelated compounds was evaluated by adding known amounts of each compound to urine samples containing near cutoff negative $( 1 5 0 \mathrm { n g / m L } )$ and near cutoff positive $( 2 5 0 ~ \mathrm { n g / m L } )$ concentrations of Oxazepam. Testing was performed in both

qualitative and semiquantitative modes. The compounds listed in the table below did not cause any positive or negative interference at the concentrations shown:

High Sensitivity $2 0 0 ~ \mathrm { { n g / m L } }$ cutoff   

<table><tr><td colspan="1" rowspan="1">Structurally UnrelatedCompounds</td><td colspan="1" rowspan="1">Tested Concentration(ng/mL)</td></tr><tr><td colspan="1" rowspan="1">6-Acetyl Morphine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">10,11 Dihydrocarbamazepine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">11-nor-Δ9-THC-COOH</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Amitriptyline</td><td colspan="1" rowspan="1">75000</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Amphetamine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Brompheniramine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Buprenorphine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Captopril</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Cimetidine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Desipramine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Dextromethorphan</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Diphenhydramine</td><td colspan="1" rowspan="1">5000030000</td></tr><tr><td colspan="1" rowspan="1">EDDP</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">EMDP</td><td colspan="1" rowspan="1">150003000</td></tr><tr><td colspan="1" rowspan="1">Fentanyl</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Fluoxetine</td><td colspan="1" rowspan="1">75000</td></tr><tr><td colspan="1" rowspan="1">Fluphenazine</td><td colspan="1" rowspan="1">75000</td></tr><tr><td colspan="1" rowspan="1">Haloperidol</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Heroin</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Hydromorphone</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Levorphanol</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Levothyroxine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Meperidine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Methadone</td><td colspan="1" rowspan="1">75000</td></tr><tr><td colspan="1" rowspan="1">Methamphetamine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Morphine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Morhpine-3β-D-glucuronide</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Morhpine-6β-D-glucuronide</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Nalbuphine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Nalorphine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Naloxone</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Naltrexone</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Naproxen</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Nifedipine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Oxaprozin</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Oxycodone</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Perphenazine</td><td colspan="1" rowspan="1">5000030000</td></tr><tr><td colspan="1" rowspan="1">Phencyclidine</td><td colspan="1" rowspan="1">10000090000</td></tr><tr><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Procyclidine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Propoxyphene</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Ranitidine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Secobarbital</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Sertraline</td><td colspan="1" rowspan="1">150007000</td></tr><tr><td colspan="1" rowspan="1">Sulpiride</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Tapentadol</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Thioridazine</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Tramadol</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Triprolidine</td><td colspan="1" rowspan="1">5000040000</td></tr><tr><td colspan="1" rowspan="1">Verapamil</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Zolpidem</td><td colspan="1" rowspan="1">5000040000</td></tr><tr><td colspan="1" rowspan="1">Enalapril</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Salicyluric Acid</td><td colspan="1" rowspan="1">100000</td></tr><tr><td colspan="1" rowspan="1">Tolmetin</td><td colspan="1" rowspan="1">100000</td></tr></table>

Interference testing of endogenous and exogenous compounds

Potential interference from endogenous and exogenous compounds on recovery of Oxazepam was evaluated by adding known amounts of each compound into urine samples containing near cutoff negative ( $\mathrm { 1 5 0 \ n g / m L ) }$ and near cutoff positive $( 2 5 0 \mathrm { n g / m L } )$ concentrations of Oxazepam for the $2 0 0 ~ \mathrm { { n g / m L } }$ cutoff. The compounds listed in the table below did not cause any positive or negative interference, either in the qualitative or semi-quantitative modes, at the concentrations shown in the table below:

200 ng/mL Cutoffs   

<table><tr><td colspan="1" rowspan="1">Compounds</td><td colspan="1" rowspan="1">TestedConc. (mg/dL)</td></tr><tr><td colspan="1" rowspan="1">Ascorbic Acid</td><td colspan="1" rowspan="1">150</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">400</td></tr><tr><td colspan="1" rowspan="1">Ethanol</td><td colspan="1" rowspan="1">1000</td></tr><tr><td colspan="1" rowspan="1">Galactose</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Glucose</td><td colspan="1" rowspan="1">1000</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">150</td></tr><tr><td colspan="1" rowspan="1">Human Serum Albumin</td><td colspan="1" rowspan="1">200</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">Oxalic acid</td><td colspan="1" rowspan="1">50</td></tr><tr><td colspan="1" rowspan="1">Riboflavin</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Sodium Chloride</td><td colspan="1" rowspan="1">1000</td></tr><tr><td colspan="1" rowspan="1">Urea</td><td colspan="1" rowspan="1">1000</td></tr></table>

# Interference Testing of Specific Gravity and pH:

Drug free urine samples with specific gravity ranging in value from 1.002 to 1.029 were split and spiked with Oxazepam to final concentrations of $1 5 0 ~ \mathrm { { n g / m L } }$ and $2 5 0 ~ \mathrm { { n g / m L } }$ for 200 $\mathrm { n g / m L }$ cutoff. Samples were evaluated in qualitative and semi-quantitative modes. The following specific gravity did not cause any positive or negative interference: 1.002, 1.004, 1.005, 1.007, 1.010, 1.012, 1.014, 1.019, 1.023, 1.025 and 1.029.

Interference from pH was evaluated by adjusting the $\mathsf { p H }$ of urine samples containing near cutoff negative $\mathrm { 1 5 0 n g / m L ) }$ and near cutoff positive $( 2 5 0 \mathrm { n g / m L } )$ concentrations of Oxazepam for the $2 0 0 ~ \mathrm { { n g / m L } }$ cutoff. The following $\mathsf { p H }$ values did not cause any positive or negative interference: 3, 4, 5, 6, 7, 8, 9, 10 and 11.

3. Assay Reportable Range: Not applicable.

4. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

Traceability: The primary calibrators are traceable to the Oxazepam drug purchased from a commercial source which is established at $9 8 \%$ purity. The concentration of the primary calibrator stocks is confirmed by LC-MS/MS from three independent laboratories.

5. Detection Limit: Not applicable.

6. Assay Cut-Off:

Characterization of how the device performs analytically around the claimed cutoff concentration is described in the precision section, VII.A.1. above.

# B Comparison Studies:

1. Method Comparison: The method comparison study was performed in accordance with CLSI Guideline EP09-A3.

One hundred and twenty-eight (128) samples were treated with $\beta$ -glucuronidase reagent prior to analysis by the CEDIATM Benzodiazepine Assay in both qualitative and semi-quantitative modes. The results were compared to LC-MS/MS where samples were also treated with $\beta .$ - glucuronidase.

The qualitative and semi-quantitative results are summarized in the tables below.

Qualitative Mode Accuracy Study with LC-MS/MS as Reference Method High Sensitivity ${ \bf 2 0 0 n g / m L }$ Cutoff   

<table><tr><td rowspan=7 colspan=1>CandidateDeviceResults</td><td rowspan=7 colspan=1>&lt; 50% ofCutoffconcentrationby LC-MS/MS (&lt;100ng/mL)</td><td rowspan=1 colspan=2>Near CutoffNegative</td><td rowspan=1 colspan=1>Near CutoffPositive</td><td rowspan=7 colspan=1>HighPositives(Greater than50% abovecutoffconcentration(&gt; 300ng/mL)</td></tr><tr><td rowspan=1 colspan=2>(Between</td><td rowspan=1 colspan=1>(Between the</td></tr><tr><td rowspan=1 colspan=2>50% below</td><td rowspan=1 colspan=1>cutoff and</td></tr><tr><td rowspan=1 colspan=2>the cutoff and</td><td rowspan=1 colspan=1>50% above</td></tr><tr><td rowspan=2 colspan=2>the cutoffconcentration</td><td rowspan=2 colspan=1>the cutoffconcentration</td></tr><tr><td rowspan=1 colspan=1>concentration</td></tr><tr><td rowspan=1 colspan=2>as determinedby LC-MS/MS) (100− 199 ng/mL)</td><td rowspan=1 colspan=1>as determinedby LC-MS/MS) (200− 300 ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=2>4*b</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>55</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=2>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Agreement among Positives: $6 8 / 6 8 = 1 0 \%$ Agreement among Negative: $5 6 / 6 0 = 9 3 \%$

Semi-Quantitative Mode Accuracy Study with LC-MS/MS as Reference Method – High Sensitivity ${ \bf 2 0 0 n g / m L }$ Cutoff   

<table><tr><td rowspan=6 colspan=1>CandidateDeviceResults</td><td rowspan=6 colspan=1>&lt; 50% ofCutoffconcentrationby LC-MS/MS (&lt;100ng/mL)</td><td rowspan=1 colspan=2>Near CutoffNegative</td><td rowspan=1 colspan=1>Near CutoffPositive</td><td rowspan=6 colspan=1>HighPositives(Greater than50% abovecutoffconcentration(&gt;300ng/mL)</td></tr><tr><td rowspan=1 colspan=2>(Between</td><td rowspan=1 colspan=1>(Between the</td></tr><tr><td rowspan=2 colspan=2>50% belowthe cutoff and</td><td rowspan=2 colspan=1>cutoff and50% above</td></tr><tr><td rowspan=1 colspan=1>the cutoff and</td></tr><tr><td rowspan=1 colspan=2>the cutoffconcentration</td><td rowspan=1 colspan=1>the cutoffconcentration</td></tr><tr><td rowspan=1 colspan=2>as determinedby LC-MS/MS) (100− 199 ng/mL)</td><td rowspan=1 colspan=1>as determinedby LC-MS/MS) (200− 300 ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=2>4*b</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>55</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=2>2</td><td rowspan=1 colspan=1>1*b</td><td rowspan=1 colspan=1>0</td></tr></table>

Agreement among Positives: $6 7 / 6 8 = 9 9 \%$ Agreement among Negative: $5 6 / 6 0 = 9 3 \%$

\*b Discordant sample results for high sensitivity $\mathbf { 2 0 0 \ n g / m L }$ cutoff   

<table><tr><td rowspan=2 colspan=1>Sample ID</td><td rowspan=1 colspan=2>EIA</td><td rowspan=1 colspan=1>LC-MS/MS</td></tr><tr><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Semi-Quantitative</td><td rowspan=1 colspan=1>TotalBenzodiazepineParent Only (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>CA160606-045*1</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>111</td></tr><tr><td rowspan=1 colspan=1>CA170605-001*1</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>171</td></tr><tr><td rowspan=1 colspan=1>CA160926-057*1</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>199</td></tr><tr><td rowspan=1 colspan=1>CA180820-014*2</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>197</td></tr><tr><td rowspan=1 colspan=1>CA170531-075*3</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>230</td></tr></table>

$^ { * 1 }$ These samples are discordant due to the presence of parent benzodiazepine and also benzodiazepine metabolites as follows: CA160606-045 contains 7-aminoclonazepam at 3155 $\mathrm { n g / m l }$ . CA170605-001 contains 7- aminoclonazepam at $5 6 0 ~ \mathrm { n g / m L }$ . CA160926-057 contains 7-aminoclonazepam at $4 1 1 \mathrm { n g / m L }$ and $1 3 ~ \mathrm { n g / m L }$ of $\mathfrak { a }$ hydroxyprazolam.

$^ { * 2 }$ Sample CA180820-014 is borderline negative by LC-MS/MS at $1 9 7 \mathrm { n g / m l }$ compared to the $2 0 0 \mathrm { n g / m l }$ cut-off.

$^ { * 3 }$ Sample CA170531-075 is borderline positive by LC-MS/MS at $2 3 0 \mathrm { n g / m l }$ compared to the $2 0 0 \mathrm { n g / m l }$ cut-off.

# 2. Matrix Comparison:

Not applicable. Urine is the only claimed matrix for the candidate device.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable.

2. Clinical Specificity: Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable.

# D Clinical Cut-Off:

Not applicable.

# E Expected Values/Reference Range:

Not applicable.

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.